Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

Author： Rolfo Christian   Raez Luis E   Russo Antonio   Reguart Noemí   Campelo Rosario García   Bronte Giuseppe   Papadimitriou Kostantinos   Silvestris Franco  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.14, Iss.1, 2014-01, pp. : 15-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Denosumab for treatment of breast cancer bone metastases and beyond

By Nangia Julie R   Ma Joseph D   Nguyen Christine M   Mendes Margaret AS   Trivedi Meghana V  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 4, 2012-04 ,pp. : 491-501

Informa Healthcare

Access to resources Recommend Favorite

Glycogen Phosphorylase as a Molecular Target for Type 2 Diabetes Therapy

By  

Current Protein and Peptide Science, Vol. 3, Iss. 6, 2002-12 ,pp. : 561-586

Bentham Science Publishers

Access to resources Recommend Favorite

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer

By Dellis Athanasios   Papatsoris Athanasios G  

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 7-10

Informa Healthcare

Access to resources Recommend Favorite

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

By Maloney Alison   Workman Paul  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 1, 2002-01 ,pp. : 3-24

Informa Healthcare

Access to resources Recommend Favorite

Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases

By Milone F.  

Biomarkers, Vol. 18, Iss. 2, 2013-03 ,pp. : 121-125

Informa Healthcare

Access to resources Recommend Favorite